USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
Discovery of New Targeted Therapies Will Replace Conventional Therapies
RELEASE DATE
28-Jan-2015
28-Jan-2015
REGION
Research Code: MAC3-01-00-00-00
SKU: LS00105-GL-MR_16946
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
LS00105-GL-MR_16946
Description
This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.
Table of Contents
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Methodology and Scope
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Recent Market Developments
Companies to Watch
Key Merger, Acquisition, and Partnership Assessment
Game-changing Strategies
Epidemiology
Epidemiology (continued)
Epidemiology (continued)
Competitive Landscape—Marketed and Pipeline Drugs in Pre-registration and Phase 3
Competitive Landscape—Pipeline Drugs in Phase 1 and Phase 2
Timeline of Product Launches/Approval
Timeline of Patent Expiries
Competitive Landscape—Pivotal Clinical Trials
Competitive Landscape—Pivotal Clinical Trials (continued)
Marketed Products Synopsis
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Pipeline Synopsis
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Product Dashboard: Tarceva® (Erlotinib)—Roche Group
Product Dashboard: Gilotrif® (Afatinib)—Boehringer Ingelheim
Product Dashboard: Avastin® (Bevacizumab)—Genentech Inc. (Roche Group)
Product Dashboard: Alimta® (Pemetrexed)—Eli Lilly and Company
Product Dashboard: XALKORI® (Crizotinib)—Pfizer Inc.
Product Dashboard: AP26113—Ariad Pharmaceuticals, Inc.
Product Dashboard: Necitumumab—Eli Lilly and Company
Product Dashboard: Nivolumab—Bristol-Myers Squibb Company and Ono Pharmaceutical
Conclusions
Legal Disclaimer
About Lung Cancer
About Lung Cancer (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
This research service examines and highlights the prevailing and the emerging trends of the Indian vaccine market to comprehend the market dynamics and identify the hidden potential growth segments. The primary objective of the study is to provide details about the overall market, including trends, and drivers and restraints. In addition, market segmentation, market share analyses and revenue forecasts are included. The research service segments the market in two ways breakdown of public and private market and a breakdown of monovalent and combination vaccines. The study discusses 10 monovalent and 15 combination vaccines and provides an estimation and forecast of market numbers and also includes competitive analysis for each vaccine.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Sumedha Pareek |
| WIP Number | MAC3-01-00-00-00 |
| Is Prebook | No |